Researchers call for EMA-style transparency regulations in Pan-America

By Maggie Lynch

- Last updated on GMT


Related tags Ema Clinical trial Data trial transparency Research

Pan-American countries should adopt EMA-style regulations to increase clinical trial transparency and streamline research, according to a recent report.

The report​, part of a series of articles published by BMJ​, provided a comparative analysis of clinical trial transparency provisions in regulations, policies, and guidelines in three Pan-American Health Organization (PAHO) jurisdictions: Brazil, Argentina, and Canada.  

The report argues that PAHO jurisdictions should follow the lead of the European Medicines Agency (EMA​), “which now has a policy that such data is not commercial confidential information, and imposes on pharmaceutical companies duty to justify why specific subsets of the data file have to be kept confidential,” ​Trudo Lemmens, one of the paper’s authors and professor of health law and policy at University of Toronto told us.

“Data is fundamentally a ‘public good’, which runs counter to the notion of commercial confidential information,”​ said Lemmens. Commercial confidential information​ refers to the set of guidelines in which a government can determine data to be confidential and unable to be viewed without a specific disclosure agreement.

Lemmens believes that clinical trial registration​ is often seen as the definitive answer to trial transparency issues. However, without access to research results and full data sets, registration is of limited value.

Disparate regulations

Lemmens called Canada is "an interesting example"​ as the country doesn’t explicitly impose clinical trial registration. However, the country is now moving further with a new data access policy, he said, citing a recent court decision in Doshi v. AG Canada, which “may turn it unwittingly in a leader in clinical trials transparency.”

The major court case Lemmens mentioned is Doshi V. AG Canada​ in which Dr. Doshi sought judicial review of his refusal to sign a confidentially agreement while trying to obtain access to clinical trial data. The ruling stated that Health Canada “could not decide whether or not data can be disclosed.”

Brazil an emerging market, compared to Canada as an established market, has transparency and research ethics regulations that seem to be sophisticated on paper, Lemmens said. Yet, budget restrictions combined with a lack of government resources hinders trial transparency in practice.

According to the report, regulations on both a national and international level aren’t coordinated and may contradict each other.

Lemmens stated, “You have research funding agencies and organizations involved in the promotion of research emphasizing data transparency, but then other agencies and organizations recognizing that data may constitute commercial confidential information and approaching data sharing as an exception rather than a rule.”

The problem is that while research governance system “clearly recognize the public role of research ethics committees, several countries fail to regulate them adequately,” ​Lemmens said.

“In order for them to really fulfill their public role, they should be fully independent and not submitted to the financial interests at stake in drug development,”​ he added.

Additionally, data access allows researchers to identify issues that are not yet known, which “becomes more and more important in the era of big data,”​ Lemmens said. He also stated that developments in trial transparency can reduce waste in clinical trials, and thus reduce costs of drug developments.

“Unfortunately, in many countries, trial registration has been embraced as if it solves the problem of hidden data,” ​Lemmens said. “It doesn’t, and countries should move further and implement data sharing along the lines of the EMA policy and not just organize trial registration.”

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

2023 State of Clinical Trial Technology Report

2023 State of Clinical Trial Technology Report

Florence Healthcare | 01-Mar-2023 | Insight Guide

Discover the trends shaping clinical trial technology in 2023, from Site Enablement to eISFs, integrations, and site-sponsor collaboration. This report...

Related suppliers

Follow us


View more